HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunoglobulin Fab Fragments

Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
Also Known As:
Fab Immunoglobulin Fragments; Immunoglobulin Fab Fragment; Immunoglobulins, Fab; Fab Fragment Immunoglobulins; Fab Fragment, Immunoglobulin; Fab Fragments, Immunoglobulin; Fragment Immunoglobulins, Fab; Fragment, Fab; Immunoglobulin Fragments, Fab; Fab Fragment; Fab Fragments; Ig Fab Fragments; Immunoglobulins, Fab Fragment
Networked: 769 relevant articles (48 outcomes, 87 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Reilly, Raymond M: 10 articles (11/2015 - 01/2005)
2. Scollard, Deborah A: 6 articles (07/2013 - 01/2005)
3. Skerra, Arne: 5 articles (04/2020 - 12/2004)
4. Allen, Theresa M: 5 articles (01/2013 - 01/2003)
5. Nieswandt, Bernhard: 4 articles (11/2017 - 05/2007)
6. Cai, Weibo: 4 articles (07/2015 - 09/2008)
7. Hong, Hao: 4 articles (07/2015 - 09/2008)
8. Goldenberg, David M: 4 articles (05/2006 - 04/2002)
9. Kondoh, Masuo: 3 articles (01/2021 - 04/2015)
10. Schlapschy, Martin: 3 articles (04/2020 - 12/2004)

Related Diseases

1. Neoplasms (Cancer)
2. Poisoning
3. Asthma (Bronchial Asthma)
4. Infections
5. Breast Neoplasms (Breast Cancer)

Related Drugs and Biologics

1. Immunoglobulin G (IgG)
2. Monoclonal Antibodies
3. Digoxin (Digitek)
4. Antigens
5. Certolizumab Pegol
6. Adalimumab (Humira)
7. Antibodies
8. Sulesomab
9. Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
10. Technetium (Technetium 99m)

Related Therapies and Procedures

1. Therapeutics
2. Radioimmunotherapy
3. Intravenous Administration
4. Injections
5. Immunotherapy